Activation of receptor for advanced glycation end products - A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis

被引:641
|
作者
Schmidt, AM
Yan, SD
Wautier, JL
Stern, D
机构
[1] Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[3] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA
[4] Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA
[5] Columbia Univ Coll Phys & Surg, Dept Cellular Biophys, New York, NY 10032 USA
[6] UFR Lariboisiere St Louis, Lab Biol Vasc & Cellulaire, Paris, France
关键词
glycoxidation; diabetes; nuclear factor-kappa B; inflammation; amyloid;
D O I
10.1161/01.RES.84.5.489
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules and engages diverse ligands relevant to distinct pathological processes. One class of RAGE ligands includes glycoxidation products, termed advanced glycation end products, which occur in diabetes, at sites of oxidant stress in tissues, and in renal failure and amyloidoses. RAGE also functions as a signal transduction receptor for amyloid beta peptide, known to accumulate in Alzheimer disease in both affected brain parenchyma and cerebral vasculature. Interaction of RAGE with these ligands enhances receptor expression and initiates a positive feedback loop whereby receptor occupancy triggers increased RAGE expression, thereby perpetuating another wave of cellular activation. Sustained expression of RAGE by critical target cells, including endothelium, smooth muscle cells, mononuclear phagocytes, and neurons, in proximity to these ligands, sets the stage for chronic cellular activation and tissue damage. In a model of accelerated atherosclerosis associated with diabetes in genetically manipulated mice, blockade of cell surface RAGE by infusion of a soluble, truncated form of the receptor completely suppressed enhanced formation of vascular lesions. Amelioration of atherosclerosis in these diabetic/atherosclerotic animals by soluble RAGE occurred in the absence of changes in plasma lipids or glycemia, emphasizing the contribution of a lipid- and glycemia-independent mechanism(s) to atherogenesis, which we postulate to be interaction of RAGE with its ligands. Future studies using mice in which RAGE expression has been genetically manipulated and with selective low molecular weight RAGE inhibitors will be required to definitively assign a critical role for RAGE activation in diabetic vasculopathy. However, sustained receptor expression in a microenvironment with a plethora of ligand makes possible prolonged receptor stimulation, suggesting that interaction of cellular RAGE with its ligands could be a factor contributing to a range of important chronic disorders.
引用
收藏
页码:489 / 497
页数:9
相关论文
共 50 条
  • [21] Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis
    Röcken, C
    Kientsch-Engel, R
    Mansfeld, S
    Stix, B
    Stubenrauch, K
    Weigle, B
    Bühling, F
    Schwan, M
    Saeger, W
    AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04): : 1213 - 1220
  • [22] Advanced glycation end-products and atherosclerosis
    Vlassara, H
    ANNALS OF MEDICINE, 1996, 28 (05) : 419 - 426
  • [24] Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes
    Basta, G
    Schmidt, AM
    De Caterina, R
    CARDIOVASCULAR RESEARCH, 2004, 63 (04) : 582 - 592
  • [25] Polymorphisms of the receptor for advanced glycation end products as vasculopathy predictor in sickle cell disease
    Safwat, Nesma Ahmed
    ELkhamisy, Mai Mohamed
    Abdel-Wahab, Soha Ezz AlArab
    Hamza, Mohamed Tarif
    Boshnak, Noha Hussein
    Kenny, Mahmoud Adel
    PEDIATRIC RESEARCH, 2021, 89 (01) : 185 - 190
  • [26] Soluble receptor for advanced glycation end products as a vasculopathy biomarker in sickle cell disease
    Nesma Ahmed Safwat
    Mahmoud Adel Kenny
    Pediatric Research, 2018, 84 : 869 - 874
  • [27] Soluble receptor for advanced glycation end products as a vasculopathy biomarker in sickle cell disease
    Safwat, Nesma Ahmed
    Kenny, Mahmoud Adel
    PEDIATRIC RESEARCH, 2018, 84 (06) : 869 - 874
  • [28] Polymorphisms of the receptor for advanced glycation end products as vasculopathy predictor in sickle cell disease
    Nesma Ahmed Safwat
    Mai Mohamed ELkhamisy
    Soha Ezz AlArab Abdel-Wahab
    Mohamed Tarif Hamza
    Noha Hussein Boshnak
    Mahmoud Adel Kenny
    Pediatric Research, 2021, 89 : 185 - 190
  • [29] Receptor for advanced glycation end products is a promising target of diabetic nephropathy
    Yamamoto, Y
    Doi, T
    Kato, I
    Shinohara, H
    Sakurai, S
    Yonekura, H
    Watanabe, T
    Myint, KM
    Harashima, A
    Takeuchi, M
    Takasawa, S
    Okamoto, H
    Hashimoto, N
    Asano, M
    Yamamoto, H
    MAILLARD REACTION: CHEMISTRY AT THE INTERFACE OF NUTRITION, AGING, AND DISEASE, 2005, 1043 : 562 - 566
  • [30] Relation between advanced glycation end products and vascular endothelial growth factor receptor in diabetic eyes
    Kanazawa, Y
    Kakehashi, A
    Inoda, S
    Kuroki, M
    Kaku, M
    Shimizu, Y
    Makino, S
    Kawakami, M
    Nagai, R
    Horiuchi, S
    DIABETOLOGIA, 1998, 41 : A19 - A19